e-ISSN 2147-2475

Hzl Arama




Mepolizumab Alan Ar Astm Hastalarnda lk SARS-CoV-2 Enfeksiyonu [Respir Case Rep]
Respir Case Rep. 2021; 10(2): 73-77 | DOI: 10.5505/respircase.2021.43650

Mepolizumab Alan Ar Astm Hastalarnda lk SARS-CoV-2 Enfeksiyonu

Emel Atayk, Gkhan Aytekin
Konya ehir Hastanesi, Erikin Allerji ve mmnoloji Klinii, Konya

iddetli akut solunum sendromu koronavirs (SARS-CoV) -2, SARS-CoV ailesiyle ayn aileye mensup, zoonotik bir viral patojendir. Bu zamana kadar, literatrde, ar astm sebebiyle mepolizumab tedavisi alan ve ayn zamanda COVID-19 gelien bir olgu bildirilmemitir. Ar non-atopik astm tedavisi iin son 6 aydr, mevcut astm tedavilerinin yannda, mepolizumab tedavisi uygulanan 61 yanda erkek hasta, Eyll 2020'de kliniimize yksek ate, son 3-4 gnde gelien koku ve tat duyusunda kayp, kuru ksrk ve nefes darl ikayetleri ile bavurdu. Hastann akcier tomografisinde her iki akcier alt lob bazal ksmlarnda yama eklinde buzlu cam dansiteleri izlendi ve hastann SARS-CoV-2 iin PCR sonucu pozitifti. Hastaya hidroksiklorokin, favipiravir ve antikoaglan tedavi baland ve hasta evde karantinaya alnd. Takiplerinde, tedavinin 5. gnnde hastann ikayetleri nemli lde rahatlad. Ar astm hastalarnn tedavisinde kullanlan ilalarin COVID-19 enfeksiyonu zerine etkilerini inceleyen geni ve kapsaml almalara ihtiya olduu aikar olmakla beraber, anti-viral etkinlii sebebiyle, bu hasta grubunda, mepolizumabn COVID-19 enfeksiyonu tedavisine olumlu katklar gz ard edilmemeli ve takip edilmelidir.

Anahtar Kelimeler: Ar astm, mepolizumab SARS-CoV-2.

First SARS-CoV-2 Infection in Patients with Severe Asthma Receiving Mepolizumab

Emel Atayk, Gkhan Aytekin
Department of Allergy and Clinical Immunology, Konya City Hospital, Konya, Turkey

Severe acute respiratory syndrome coronavirus (SARS-CoV)-2 is a zoonotic viral pathogen belonging to the same family as SARS-CoV. To the best of our knowledge, no case that was receiving mepolizumab for severe asthma and that developed COVID-19 has been reported to date in literature. In September 2020, a 61-year-old male patient undergoing monthly mepolizumab treatment for the last 6 months, in addition to his current asthma treatment, was admitted to our clinic with complaints of high fever (38-38.50C), loss of senses of taste for 3-4 days, as well as nonproductive cough and shortness of breath. Patchy ground-glass densities were observed in basal parts of lower lobes of both lungs, and the patient recorded a positive nasopharyngeal real-time PCR SARS-CoV-2 test. The patient was initiated on hydroxychloroquine, favipiravir and an anticoagulant, and home quarantine was recommended. The patient's complaints had relieved significantly by day 5 of the treatment. There is a need for larger and more extensive studies on the effect of medications used for the treatment of patients with severe asthma on COVID-19 infection, and due to its antiviral effects, the potential favorable contribution of mepolizumab to the treatment of COVID-19 infection in this patient group should be monitored.

Keywords: Severe asthma, mepolizumab SARS-CoV-2.

Emel Atayk, Gkhan Aytekin. First SARS-CoV-2 Infection in Patients with Severe Asthma Receiving Mepolizumab. Respir Case Rep. 2021; 10(2): 73-77

Sorumlu Yazar: Emel Atayk, Trkiye
LookUs & Online Makale